Long-term LUNA3 data showed rilzabrutinib delivered durable platelet responses, reduced bleeding and fatigue, and maintained safety in ITP.
David Kuter, MD, DPhil
Advertisement
David Kuter, MD, DPhil, is director of clinical hematology at Massachusetts General Hospital and professor of medicine at Harvard Medical School.
Articles by David Kuter, MD, DPhil
The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy.
Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.
Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5